Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CT5P | ISIN: SE0016278154 | Ticker-Symbol: 999
Frankfurt
28.08.24
10:22 Uhr
0,666 Euro
0,000
0,00 %
1-Jahres-Chart
HILBERT GROUP AB Chart 1 Jahr
5-Tage-Chart
HILBERT GROUP AB 5-Tage-Chart
ACCESSWIRE
305 Leser
Artikel bewerten:
(1)

Hilbert Group AB has Carried out a Directed Issue of SEK 21.2 million

STOCKHOLM, SE / ACCESSWIRE / March 04, 2024 / Hilbert Group (STO:HILB-B) (FRA:999) THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLICATED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION IN WHICH SUCH ACTION IN WHOLE OR IN PART, IS SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN HILBERT GROUP AB (PUBL) IN ANY JURISDICTION. PLEASE REFER TO THE "IMPORTANT INFORMATION" SECTION BELOW.

Summary

Hilbert Group AB (publ) (" Hilbert Group " or the " Company ") has carried out a directed issue of 5,300,000 B-shares at a subscription price of SEK 4.00 (the " Directed Issue "). Hilbert Group will receive proceeds of SEK 21.2 million before related transaction costs.

The Directed Issue has been resolved by the Board of Directors based on an authorization by the Annual General Meeting.

Comments by the CEO

Hilbert Group's CEO Niclas Sandström comments: "The crypto market has staged a strong recovery during the past three months. The flip side is that this has re-priced a lot of the appealing M&A opportunities that came in the wake of the bear market where many digital asset managers were struggling - and these opportunities now need to be re-negotiated. The window of opportunity is still here but likely to be gone in six months' time. The purpose of the capital raise at hand is twofold:

  • To have a little extra dry powder for a cash component, enabling a swifter close in some of the candidate deals that we are looking at.
  • To provide working capital to facilitate Hilbert's growth until asset management is profitable - this is expected to happen in the second half of 2024 based on current investor pipelines."

The Directed Issue

The Directed Issue consists of 5,300,000 new B-shares at a subscription price of SEK 4.00 per share. The subscription price corresponds to a discount of approximately 3.6 percent of the closing price on Nasdaq First North on March 1 and a discount of approximately 11.7 percent of the volume-weighted average price (VWAP) of the Company's B-shares on Nasdaq First North Growth Market during the period February 19 - March 1, 2024. The Company will receive proceeds of SEK 21.2 million before related transaction costs.

The Directed Issue is subscribed for by a group of investors in Norway and Sweden with subscriptions between SEK 0.2 and 5 million. Significant subscriptions was made by Tigerstaden AS, Buntel AB and Gryningskust Holding AB.

The Directed Issue entails an increase in the number of shares in the Company by 5,300,000 B-shares to in total 61,221,375 shares divided into 8,500,000 A-shares and 52,721,375 B-shares. The share capital increases with SEK 265,000, from SEK 2,796,068.75 to SEK 3,061,068.75. The Directed Issue thereby entails a dilution effect for current shareholders of approximately 8.66 percent of the share capital and 3.85 percent of the votes in the Company, calculated as the number of newly issued shares divided by the total number of shares after the Directed Issue.

The Board of Director's deliberations on the Directed Issue

The Board has considered alternative financing structures, including to carry out a rights issue. In the opinion of the Board a directed share issue meets the company's financing needs in a more efficient way than a rights issue, not least due to the costs to have a rights issue guaranteed. Further, a rights issue would normally have to be made at a significant discount, which would lead to greater dilution effects for those existing shareholders who would not be able to participate in a rights issue. From a shareholder perspective, a rights issue at a discount entails a risk of a significant negative effect on the share price. After an overall assessment of the current market situation, the Board has concluded that the best financing alternative for the shareholders is to carry out the Directed issue on the current terms. The issue price has been determined through negotiations on arm's length basis with the investors. The Board of Directors concludes that the issue price reflects current market conditions.

For additional information, please contact:
Niclas Sandström
CEO Hilbert Group AB
Phone: +46 8 502 353 00
Email: ir@hilbert.group

Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Hilbert Group in any jurisdiction, neither from Hilbert Group nor from someone else.

Any investment decision in connection with the Directed Issue must be made on the basis of all publicly available information relating to the Company and the Company's shares. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the " Securities Act "), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States of America (including its territories and possessions, any state of the United States and the District of Columbia) or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release is not a prospectus for the purposes of the Prospectus Regulation (EU) 2017/1129 (the " Prospectus Regulation ") and has not been approved by any regulatory authority in any jurisdiction. Hilbert Group has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection with the Directed Issue. In any member state of the EEA, this communication is only addressed to and is only directed to qualified investors in that member state within the meaning of the Prospectus Regulation.

Forward-looking statements
This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or expectations about the Company's future results, financial condition, liquidity, development, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "estimate", "will", "can", "assume", "should", "could", and, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and can be subject to change. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or Nasdaq First North Growth Market's rule book for issuers. Potential investors should not place undue reliance on the forward-looking information contained herein.

About Us

Hilbert group is a quantitative investment company specializing in algorithmic trading strategies in digital asset markets.

Hilbert Group is a Swedish public company and is committed to providing operational infrastructure, risk management and corporate governance that meets the ever-increasing demands of institutional investors.

Hilbert Group is listed on Nasdaq First North Growth Market (ticker HILB B) with Redeye AB as Certified Adviser.

For more information, visit: www.hilbert.group

This information is information that Hilbert Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-03-04 08:55 CET.

Attachments

Hilbert Group AB (publ) has carried out a directed issue of SEK 21.2 million

SOURCE: Hilbert Group



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.